Stockreport

BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet [Yahoo! Finance]

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
PDF The drugmaker will ?pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last ?close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premar [Read more]